CompletedPhase 1/2

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

United States25 participantsStarted 2013-03-04

Plain-language summary

The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Provides written informed consent * Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis treatment or treatment with other drugs that may alter angiogenesis * Able to remain still for duration of each imaging procedure (about one hour) Exclusion Criteria: * Pregnant or nursing * Contraindication to MRI * History of renal insufficiency (only for MRI contrast administration)

What they're measuring

Change From Baseline in Maximum Standard Uptake Values (SUVmax)

Timeframe: At baseline and 6 weeks

Trial details

NCT IDNCT01806675

SponsorSanjiv Sam Gambhir

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-12-07

Results submitted2019-08-14

View on ClinicalTrials.gov More Adult Giant Cell Glioblastoma trials